Anti-angiogenic effects of biotechnological therapies in rheumatic diseases

Figures & data

Table 1 Mechanisms of action of biothecnological drugs and their role in angiogenesis in rheumatic diseases

Biological drug	Mechanism of action	Role in angiogenesis in rheumatic diseases	References
Infliximab	TNF-α inhibition	Reduction of serum VEGF levels in RA	^Citation33^–^Citation36
Adalimumab	TNF-α inhibition	Not studied
Etanercept	TNF-α inhibition	Not studied
Golimumab	TNF-α inhibition	Not studied
Certolizumab	TNF-α inhibition	Not studied
Tocilizumab	Inhibition of IL-6 by binding to IL-6 receptor	Angiogenesis inhibition in synovial tissues obtained from RA patients	^Citation40
Abatacept	Inhibition of T-cell activation by blocking interaction of CD80/CD86 receptors to CD28	Reduction of serum levels of ADAM17 and CX3CL1 in RA. Reduction of CX3CL1 in RA synovial fluids	^Citation13,Citation44
Rituximab	Depletion of B cell by binding to the CD20 antigen	Reduction of serum levels of MMP-1, MMP-3, MMP-9, thrombomodulin, P-selectin, and VEGF in ANCA-associated vasculitis	^Citation53
Anakinra	Inhibition of IL-1 by binding to IL-1 receptor	Angiogenesis inhibition (evaluated only in animal models of arthritis)	^Citation58
Belimumab	BAFF inhibition	Not studied
Secukinumab	IL-17 inhibition	Not studied
Ustekinumab	IL-12 and IL-23 inhibition	Not studied

Abbreviations: ANCA, antineutrophil cytoplasmatic antibody; BAFF, B-cell activating factor; CTLA-4, cytotoxic T-lymphocyte antigen 4; IL, interleukin; MMP, matrix metalloproteinase; RA, rheumatoid arthritis; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.

PaleologEMYoungSStarkACMcCloskeyRVFeldmannMMainiRModulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritisArthritis Rheum199841125812659663484

 PubMed Web of Science ®Google Scholar

Cordiali-FeiPTrentoED’AgostoGEffective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesionsAnn N Y Acad Sci2007111057858917911474

 PubMed Web of Science ®Google Scholar

HirohataSAbeAMurasawaAKanamonoTTomitaTYoshikawaHDifferential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritisMod Rheumatol20161517

 Google Scholar

ZhouLLuGShenLWangLWangMSerum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significanteBiomed Res Int2014201462712624511540

 PubMed Web of Science ®Google Scholar

UmemuraMIsozakiTIshiiSReduction of serum ADAM17 level accompanied with decreased cytokines after abatacept therapy in patients with rheumatoid arthritisInt J Biomed Sci20141022923525598752

 PubMedGoogle Scholar

MonachPATomassonGSpecksUCirculating markers of vascular injury and angiogenesis in antineutrophilcytoplasmic antibody-associated vasculitisArthritis Rheum2011633988399721953143

 PubMed Web of Science ®Google Scholar

CoxonABolonBEstradaJInhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritisArthritis Rheum2002462604261212384918

 PubMed Web of Science ®Google Scholar